Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results

Balaxi Pharmaceuticals Financial Results

Balaxi Pharmaceuticals approved audited FY26 financial results and recommended re-appointing Ms. Akshita Ostwal as Independent Director. The company also received a manufacturing license for its new plant.

Source

NSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Balaxi Pharmaceuticals Ltd: key numbers

Share price
₹20.33
Market cap
₹112.2 Cr
Revenue (annual)
₹270.2 Cr
Net profit (annual)
₹1.42 Cr
P/E (TTM)
46.3×Sector 46.1×
Promoter holding
65.99%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Balaxi Pharmaceuticals Ltd

All →

Other financial results announcements

All →